Bioengineered Chewing Gum Shows Promise in Reducing Oral Microbes Linked to Cancer
Researchers at the University of Pennsylvania School of Dental Medicine have developed a bioengineered chewing gum that targets and reduces levels of harmful oral microbes associated with worse outcomes in oral cancers. The innovative approach leverages plant-based biotechnology to deliver therapeutic proteins directly in the mouth, offering a potential low-cost, accessible strategy for oral cancer prevention and adjunct therapy.
How the Bioengineered Gum Works
The chewing gum is designed to express antimicrobial and antiviral proteins in plant tissues, specifically using lettuce and tobacco plants as biofactories. When chewed, the gum releases these proteins into the oral cavity, where they target three specific microbes: Fusobacterium nucleatum, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. These bacteria are known to promote inflammation, disrupt the oral microbiome, and are frequently found in higher concentrations in patients with oral squamous cell carcinoma, particularly those with poor prognoses.
According to the study led by Henry Daniell, Ph.D., a professor in the Department of Biochemistry and Director of the Center for Plant Translational Research at Penn Dental Medicine, the antimicrobial proteins in the gum effectively reduce the bacterial load without disrupting beneficial oral flora. This selectivity is critical, as broad-spectrum antibiotics can cause microbial imbalances that may lead to other health complications.
Research Findings and Significance
Published in April 2026, the preclinical study demonstrated that regular use of the bioengineered gum led to a measurable decrease in the levels of the three target pathogens. Importantly, the reduction was achieved without altering the overall diversity of the oral microbiome or depleting commensal bacteria that contribute to oral health.
The research team emphasized that the gum is not intended to replace standard cancer treatments but could serve as a complementary tool in managing microbial contributors to disease progression. Because the gum is non-invasive, easy to use, and potentially inexpensive to produce at scale, it holds particular promise for use in low-resource settings where access to advanced diagnostics and therapies is limited.
Advantages of Plant-Based Drug Delivery
Using plants to produce therapeutic proteins offers several advantages over traditional microbial fermentation systems. Plant-based expression avoids the risk of contamination with human pathogens, eliminates the need for expensive fermentation infrastructure, and allows for oral delivery without purification — the gum itself is the delivery vehicle.
This method, known as molecular farming, has been explored for various applications, including vaccine production and enzyme replacement therapy. In this case, the Daniell Lab’s work builds on years of research into using edible plants to produce biopharmaceuticals that are stable, safe, and effective when delivered via oral mucosal absorption.
Future Directions
The next steps for the research team include advancing to clinical trials to evaluate the gum’s safety and efficacy in human subjects, particularly individuals with precancerous oral lesions or those at high risk for oral cancer due to factors like tobacco use, HPV infection, or poor oral hygiene.
If successful in clinical settings, the bioengineered chewing gum could represent a novel paradigm in preventive oncology — one that integrates synthetic biology, plant biotechnology, and everyday consumer habits to combat disease at its earliest stages.
As of April 23, 2026, the study remains in the preclinical phase, with findings published through Penn Today and the Daniell Lab’s official channels. No commercial product is currently available, and the gum is not yet approved for public use by regulatory agencies such as the U.S. Food and Drug Administration (FDA).